The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Infectious Conjunctivitis (Disorder)

In brief

The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

Key facts

Study ID

NCT05356793

Run by

Sacsh

People needed

30

Starts

2021-03-01

Expected to finish

2022-03-28

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.
• At least 18 years of age.
• Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.
• Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.
• A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.
• All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.
• Patients will require a rating of 1 (mild) for bulbar conjunctival injection.

You may not qualify if…

• Conjunctivitis greater than 72 hours after initial ocular symptoms
• Corneal ulcer, endophthalmitis, or any other confounding infection of the eye
• Patients taking topical anti-inflammatory medications on a chronic basis
• Known steroid glaucoma responders
• Active herpes ocular infection
• Pregnant women
• Known allergy to chlorhexidine

Where it is running

• Jacqueline Dauhajre, MD — Jackson Heights, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.